Neovasculgen


Neovasculgen is a gene-therapy drug for treatment of peripheral artery disease , including critical limb ischemia ; it delivers the gene encoding for vascular endothelial growth factor(VEGF). [1] [2] Neovasculogen is a plasmid encoding the CMV promoter and the amino acid 165 form of VEGF. [3] [4] It was developed by the Human Stem Cells Institute in Russia and approved in Russia in 2011.

References

  1. Jump up^ AdisInsightVascular Endothelial Growth Factor Gene Therapy – HSCIPage accessed 5 June 2016
  2. Jump up^ “Gene Therapy for PAD Approved” . December 6, 2011 . Retrieved 5 August 2015 .
  3. Jump up^ Eurolab. Neovasculogen listing in EurolabPage accessed 4 August 2015
  4. Jump up^ Deev, R .; Bozo, I .; Mzhavanadze, N .; Voronov, D .; Gavrilenko, A .; Chervyakov, Yu .; Staroverov, I .; Kalinin, R .; Shvalb, P .; Isaev, A. (March 13, 2015). “pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Chronic Patients With Lower Limb Ischemia”. Journal of cardiovascular pharmacology and therapeutics . 20 (5): 473-82. doi : 10.1177 / 1074248415574336 . PMID  25770117 .

Leave a Reply

Your email address will not be published. Required fields are marked *